CompletedPhase 2NCT04084444

Safety and Efficacy of T8 on Treating Chronic Abnormal Immune Activation in HIV/AIDS Patients

Studying Acquired immunodeficiency

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Principal Investigator
Taisheng Li, PhD
Peking Union Medical College Hospital
Intervention
T8 tablet 0.5mg(drug)
Enrollment
151 enrolled
Eligibility
18-65 years · All sexes
Timeline
20192022

Study locations (9)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04084444 on ClinicalTrials.gov

Other trials for Acquired immunodeficiency

Additional recruiting or active studies for the same condition.

See all trials for Acquired immunodeficiency

← Back to all trials